Stocks & Investing
Stocks and Investing
Stocks and Investing
Thu, January 19, 2023
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
[ 12:00 AM ] - United States, WOPRAI
Silvan Tuerkcan Maintained (VOR) at Buy with Decreased Target to $12 on, Jan 19th, 2023
Silvan Tuerkcan of JMP Securities, Maintained "Vor Biopharma Inc." (VOR) at Buy with Decreased Target from $15 to $12 on, Jan 19th, 2023.
Silvan has made no other calls on VOR in the last 4 months.
There are 2 other peers that have a rating on VOR. Out of the 2 peers that are also analyzing VOR, 0 agree with Silvan's Rating of Hold.
These are the ratings of the 2 analyists that currently disagree with Silvan
- Matthew Biegler of "Oppenheimer" Maintained at Buy with Decreased Target to $18 on, Monday, November 14th, 2022
- Carter Gould of "Barclays" Maintained at Buy with Decreased Target to $15 on, Friday, November 11th, 2022
